Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00031980
First received: March 8, 2002
Last updated: April 24, 2010
Last verified: May 2008
  Purpose

RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer.

PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.


Condition Intervention Phase
Anemia
Leukemia
Neutropenia
Thrombocytopenia
Drug: cyclosporine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Supportive Care
Official Title: Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Frequency of cytopemic response [ Designated as safety issue: No ]

Study Start Date: March 2002
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine.

OUTLINE: This is a multicenter study.

Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 4 months for 1 year and then every 6 months for 9 years.

PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 3 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of T-cell large granular lymphocytic leukemia

    • Increased numbers of large granular lymphocytes in peripheral blood smears
    • CD3+CD8+CD57+ immunophenotype by flow cytometry AND
    • CD3+CD57+ cell count at least 2,000/mm^3 OR
    • CD3+CD57+ cell count at least 500/mm^3 with clonal T-cell receptor beta gene rearrangement
  • Patients must have at least 1 of the following:

    • Severe neutropenia (absolute neutrophil count (ANC) less than 500/mm^3)
    • Neutropenia (ANC less than 1,000/mm^3) and recurrent infections
    • Anemia (hemoglobin less than 9 g/dL)
    • Thrombocytopenia (platelet count less than 50,000/mm^3)

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • NCI CTC 0-3

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • Bilirubin no greater than 2 times upper limit of normal (ULN)

Renal:

  • Creatinine no greater than 2 times ULN

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No concurrent chemotherapy

Endocrine therapy:

  • No concurrent hormonal therapy except steroids for adrenal failure or hormones for nondisease-related conditions (e.g., insulin for diabetes)
  • No concurrent dexamethasone or other steroidal antiemetics

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • No prior cyclosporine therapy for this leukemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00031980

Locations
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Cancer and Leukemia Group B
Investigators
Study Chair: Maria R. Baer, MD University of Maryland Greenebaum Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Monica M. Bertagnolli, Cancer and Leukemia Group B
ClinicalTrials.gov Identifier: NCT00031980     History of Changes
Other Study ID Numbers: CDR0000069246, CALGB-10003
Study First Received: March 8, 2002
Last Updated: April 24, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I chronic lymphocytic leukemia
stage II chronic lymphocytic leukemia
stage III chronic lymphocytic leukemia
stage IV chronic lymphocytic leukemia
T-cell large granular lymphocyte leukemia
anemia
neutropenia
thrombocytopenia

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia
Thrombocytopenia
Neutropenia
Leukemia, Large Granular Lymphocytic
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Blood Platelet Disorders
Hematologic Diseases
Agranulocytosis
Leukopenia
Leukocyte Disorders
Leukemia, T-Cell
Cyclosporins
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on September 18, 2014